Information Provided By:
Fly News Breaks for March 20, 2018
HQY
Mar 20, 2018 | 07:50 EDT
Baird analyst Mark Marcon raised his price target on HealthEquity to $61 from $49 after the company finished "another great year," with Q4 earnings mostly beating estimates. The analyst has a Neutral rating on the shares, telling investors in a research note that while fundamentals remain "excellent," deserved premium valuation keeps him on the sidelines "in hopes of better buying opportunity."